InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,274.00
(
-0.69%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
85.01
(
0.37%
)
Bitcoin
65,065.40
(
0.15%
)
Post# of 252273
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 117736

Wednesday, 04/06/2011 4:36:53 PM

Wednesday, April 06, 2011 4:36:53 PM

Post# of 252273
Re: Using IL28B status to dictate treatment

I’m inclined to agree with ThomasS that giving Telaprevir to only the patients who fail to achieve RVR on SoC is likely to backfire in terms of economics (in addition to being bad medicine).

Not all patients just those with CC genotype. I'm sure it will not be used in the US but unfortunately, payors in other countries might want that. I do think that IL28B status should be used but the other way around - not treat patients who will likely not respond to interferon.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up